SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. disclosed today that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier(R) will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN). Dr. Vijay Kher, principal investigator of the Hemopurifier(R) studies and Director of Nephrology at the Fortis Hospital in New Delhi, India will present and discuss Hemopurifier(R) treatment results from 10am-12pm pacific time on October 30th, 2009. The event is being held at The San Diego Convention Center in San Diego, California.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)
“We are honored that Dr. Kher has been invited to travel from India to present our clinical data at the largest annual gathering of Nephrologists,” stated Aethlon Chairman and CEO, Jim Joyce. The Aethlon Hemopurifier(R) is the first-in-class medical device able to selectively remove viruses and immunosuppressive proteins from the bloodstream. In HCV care, the device targets to improve patient cure rates as an adjunct to accelerate and enhance the performance of current and future iterations of standard of care drug therapy.
About ASN
More than 11,000 physicians and scientists, all committed to preventing kidney disease and making life better for patients, work together as members of the American Society of Nephrology (ASN). Whether providing expert care to patients, performing cutting-edge medical research, or training the next generation of kidney experts, these nephrologists change lives. Through advocacy, ASN informs policymakers about issues of importance to kidney doctors and their patients. ASN also funds research, convenes world-renowned meetings and generates educational tools that enable nephrologists to be most effective. Building on a 40-year history, ASN brings rigor, integrity, and ingenuity to all its work. Visit www.asn-online.org for additional detail.
About Aethlon Medical
Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier(R) represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier(R) seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier(R) to reduce viral loads and other disease conditions, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company’s ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings.
SOURCE Aethlon Medical, Inc.
CONTACT: Jon Cunningham of RedChip Companies, Inc., 1-800-733-2447, ext.
107, Jon@redchip.com, for Aethlon Medical, Inc.; Jim Joyce, Chairman, CEO,
+1-858-459-7800 ext. 301, jj@aethlonmedical.com, or Jim Frakes, Senior VP
Finance, +1-858-459-7800 ext. 300, jfrakes@aethlonmedical.com, both of
Aethlon Medical, Inc.
Web site: http://www.aethlonmedical.com/
